ArticleAvicenna journal of phytomedicine
Protective role of zeaxanthin on acrylamide-induced neurotoxicity in Wistar rats.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acrylamide-Induced Neurotoxicity Is Mitigated by Curcumin and Its Nano Lipid Carrier Formulation in Albino Rats.Environmental toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The Maillard reaction generates acrylamide (ACR), a toxic compound commonly found in laboratory and industrial settings. ACR exposure, both short-term and long-term, can damage various organs, notably the central nervous system, through oxidative stress, inflammation, and apoptosis. This study explores the potential neuroprotective effects of zeaxanthin (ZEA), known for its antioxidant, anti-inflammatory, and anti-apoptotic properties, against ACR-induced toxicity in the rat cerebral cortex. Materials and Methods: Rats were subjected to ACR exposure (50 mg/kg, intraperitoneal injection) for 11 days and subsequently, treated with ZEA (20-80 mg/kg, intragastric gavage) for either 11 or 20 days to assess both preventive and therapeutic effects. Locomotor behavior was evaluated using a gait score test, while biochemical analyses measured malondialdehyde (MDA) and glutathione (GSH) levels, inflammatory markers interleukin-1 beta (IL-1β), and tumor necrosis factor-alpha (TNF-α), and apoptotic markers (cleaved caspase-3) in the cerebral cortex. Results: ACR exposure impaired locomotion in the animals, but ZEA treatment significantly improved gait scores when administered preventatively (from days 6-11) or therapeutically (from days 6-20). ACR also led to increased MDA levels and depleted GSH content in brain tissue, and it elevated IL-1β, TNF-α, and cleaved caspase-3 in the cerebral cortex. However, ZEA supplementation, along with vitamin E, effectively reversed these alterations compared to the ACR-exposed group. Conclusion: In conclusion, ZEA demonstrates both preventive and therapeutic effects against ACR-induced neurotoxicity. These findings suggest that ZEA could serve as an effective preventive agent by countering ACR-induced damage through its antioxidant, anti-inflammatory, and anti-apoptotic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.